ClinicalTrials.gg
Not yet recruitingNCT07717164Updated Jul 28, 2026

PRAISE-IR Versus CIBMTR Controls

An observational study in ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myeloid Leukemia) and MDS (Myelodysplastic Syndrome), sponsored by Miltenyi Biomedicine GmbH. Not yet recruiting at 1 site in United States. Open to participants aged 1 Year to 66 Years. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Miltenyi Biomedicine GmbH · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
51
Ages
1 Year to 66 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,138 studies in Leukemia, Myeloid, Acute with a site in United States — 309 open to participants now, 463 under way, 24 of them phase 3. Leukemia, Myeloid, Acute · United States.

Planned enrollment
78th of 126
51 · median 98
Started
2026
with 72 others
Observational
126 of 2,138
29 open now
Primary completion
2026-09
later than 97 of 461 live
Registered
2,126th of 2,138
by date

Among the 2,138 studies in Leukemia, Myeloid, Acute with a site in United States, this one is the 78th largest by planned enrollment of the 126 observational ones that give a count, is one of 73 that started in 2026, is one of 126 observational ones, reaches primary completion later than 97 of the 461 other live ones, and was the 2,126th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

309 of the 2,138 studies in Leukemia, Myeloid, Acute with a site in United States are open now. Recruiting first, the newest first:

304 more — sign in →

All 309 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 1 Year to 66 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,138 studies in Leukemia, Myeloid, Acute with a site in United States, or all of them as a file.
02

Study summary

The rationale to conduct this RWE study is to provide data to support the safety of CD34 selected grafts versus T replete PBSC transplants to address concerns about increased TRM in CD34 selected graft recipients.

Read the detailed description

Comparison of the PRAISE -IR ("Phase 2 Study of Personalized r-ATG Dosing to Improve Survival Through Enhanced Immune Reconstitution in Pediatric and Adult Patients Undergoing Ex-vivo CD34-Selected Allogeneic-HCT", NCT04872595) study population with CIBMTR controls

03

Conditions studied

  • ALL (Acute B-Lymphoblastic Leukemia)
  • AML (Acute Myeloid Leukemia)
  • MDS (Myelodysplastic Syndrome)
04

Who can participate

Ages eligible
1 Year to 66 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Disease: Patients with AML, MDS, and ALL

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Arm A: Model-based ATG dosing CD34-selection (PRAISE-IR population)

  • Patients who participated in the PRAISE-IR single center phase II study
  • Patient age at transplant: ≥ 1 year and \< 66 years
  • HLA 8/8 MRD or MUD
  • Conditioning intensity: myeloablative
  • Conditioning regimens: Model-based ATG with TBI/Thiotepa/Cyclophospamide (TBI/Thio/Cy) or Busulfan/Melphalan/Fludarabine (Bu/Mel/Flu).
  • Morphologic complete remission at the time of alloHCT Arm B: Standard ATG dosing CD34-selection (CIBMTR population)
  • First AlloHCT in the US between 2021-2023
  • Patient age at transplant: ≥ 1 year and \< 66 years
  • Disease: Patients with AML, MDS, and ALL
  • HLA 8/8 MRD or MUD
  • Peripheral blood stem cell allograft
  • Conditioning intensity: myeloablative conditioning
  • Conditioning regimens: standard dose ATG (2.5 mg/kg/day given on Day -4 and Day -3)
  • prophylaxis: ex vivo CD34 selection
  • Morphologic complete remission at the time of alloHCT Arm B*:Standard ATG dosing CD34-selection (BMT CTN 1301 population)
  • Patients in BMT CTN 1301, who received the CD34-selected graft
  • Patient age at transplant: ≥ 1 year and \< 66 years
  • Disease:Patients with AML, MDS, and ALL
  • HLA 8/8 MRD or MUD
  • Peripheral blood stem cell allograft
  • Conditioning intensity: myeloablative conditioning
  • Conditoning regmens: TBI/Thiotepa/Cyclophospamide (TBI/Thio/Cy) or Busulfan/Melphalan/Fludarabine (Bu/Mel/Flu) and standard dose ATG (2.5 mg/kg/day given on Day -4 and Day -3)
  • GVHD prophylaxis: ex vivo CD34 selection
  • Morphologic complete remission at the time of alloHCT Arm C: Control CIBMTR population
  • First AlloHCT in the US between 2021-2023
  • Patient age at transplant: ≥ 1 year and \< 66 years
  • Disease:Patients with AML, MDS, and ALL
  • HLA 8/8 MRD or MUD
  • Peripheral blood stem cell
  • Conditioning intensity: myeloablative conditioning
  • Conditioning regimens: Busulfan/Cyclophosphamide (Bu/Cy), Busulfan/Fludaranbine (Bu/Flu), Cyclophosphamide/TBI (Cy/TBI), TBI/Etopsoside
  • GVHD prophyalxis: / CNI or PTCy-based
  • CNI-based: CNI (tacrolimus or ciclosporin) plus MTX
  • PTCy-based: Cyclophosphamide on day +3 and +4 (50 mg/kg/d) combined with CNI and mycophenolate mofetil (MMF)

Exclusion criteria

Exclusion Criteria:

Patients will be entered into this trial only if they meet none of the following criteria:

Arm A: Model-based ATG dosing CD34-selection (PRAISE-IR population)

  • HLA \<8/8 MRD or MUD Arm B: Standard ATG dosing CD34-selection (CIBMTR population)
  • Patients who participated in the PRAISE-IR study
  • Patients who did not sign consent for research
  • Patient transplanted at a center that does not meet CIBMTR data quality standards
  • Use of CNI-(Tac/MTX) or PTCy-based prophylaxis Arm B*:Standard ATG dosing CD34-selection (BMT CTN 1301 population)
  • Patients who did not sign consent for research
  • Patient transplanted at a center that does not meet CIBMTR data quality standards
  • Use of CNI- or PTCy-based GVHD prophylaxis Arm C: Control CIBMTR population
  • Patients who did not sign consent for research
  • Patient transplanted at a center that does not meet CIBMTR data quality standards
  • Use of ATG and/or alemtuzumab
  • Patients who received PTCy with sirolimus (and not a CNI)
  • Use of ex vivo CD34 selection
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
51 participants (estimated)
Patient registry
No

Groups and cohorts

  • Arm A: Model-based ATG dosing CD34-selection (PRAISE-IR population)

    CliniMACS CD34 Reagent System

  • Arm B: Standard ATG dosing CD34-selection (CIBMTR population)

    Intervention: CliniMACS CD34 Reagent System

  • Arm B*:Standard ATG dosing CD34-selection (BMT CTN 1301 population)

    CliniMACS CD34 Reagent System

  • Arm C: Control CIBMTR population
06

What researchers measure

Primary outcomes

  1. Comparison of OS between PRAISE-IR study participants (Arm A) with CIBMTR control participants who have received a CD34 selected graft and standard dose ATG (Arm B) with the goal of demonstrating superiority of Arm A.

    Comparison of overall survival (OS) between PRAISE-IR study participants (Arm A) with CIBMTR control participants who have received a CD34 selected graft and standard dose ATG (Arm B). Note: If the number of participants meeting the criteria for Arm B is insufficient for 1:1 matching, Arm A could be compared with the CD34 selection group from the BMT CTN1301 study (Arm B\*). Comparison of OS between PRAISE-IR study participants (Arm A) with CIBMTR control patients who have received standard of care (SoC) allogeneic hematopoietic stem cell transplantation (alloHCT) without CD34 selection with post transplantation cyclophosphamide (PTCy) and Calcineurin inhibitor (CNI)/Methotrexate (MTX) for GVHD prophylaxis (Arm C).

    Time frame: two years

Secondary outcomes

  1. Acute GVHD, grades II-IV

    Acute Graft-versus-Host Disease (GVHD), grades II-IV

    Time frame: two years

  2. Chronic GVHD

    Chronic Graft-versus-Host Disease (GVHD)

    Time frame: two years

  3. Hematologic recovery (time to neutrophil engraftment and time to platelet engraftment)

    Hematologic recovery (time to neutrophil engraftment and time to platelet engraftment)

    Time frame: two years

  4. Rate of primary graft failure

    Rate of primary graft failure

    Time frame: two years

  5. Non-relapse mortality

    Non-relapse mortality

    Time frame: two years

  6. Relapse

    Relapse

    Time frame: two years

  7. Relapse-free survival

    Relapse-free survival

    Time frame: two years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2026; primary completion for Sep 2026, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2026
First posted
Jul 21, 2026
StartEst.
Jul 31, 2026
Primary completionEst.
Sep 20, 2026
CompletionEst.
Sep 30, 2026
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07717164
Lead sponsor
Miltenyi Biomedicine GmbH
Responsible party
Sponsor
First posted
Jul 21, 2026
Start date
Jul 31, 2026 (estimated)
Primary completion
Sep 20, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Jul 28, 2026

Study contacts

Michaela Malchow
Contact
Michaela.Malchow@miltenyi.com
+49 15117151746

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion